… We aimed to evaluate the safety and virological efficacy of molnupiravir in vaccinated and …
molnupiravir for adults with documented SARS-CoV-2 infection: 800 mg every 12 h for 5 days. …

… (RNA) virus has caused more … SARS-CoV-2 variants and protection of immunosuppressed
patients [7]. This stresses the urgency of investigating and implementing efficient and safe …

… been immunised against SARSCoV-2 and had SARS-CoV-2 infection and symptoms within
5 days of enrollment. Subjects were randomly allocated to receive 800 mg of molnupiravir or …

Background Little is known about the real-world effectiveness of oral antivirals against the
SARS-CoV-2 omicron (B.1.1.529) variant. We aimed to assess the clinical effectiveness of two …

… Here, a systematic review on the cumulative evidence of molnupiravir safety and anti-viral
activity is … Negativity of SARS CoV-2 RT-PCR was early observed in Molnupiravir group in …

… The initial SAD cohort included dosing of two sentinel subjects, each one assigned to either
molnupiravir or placebo. The safety results for the sentinel group were reviewed 24 h post-…

… effect of the combination of Molnupiravir and Favipiravir in the SARS-CoV-2 hamster infection
… who received molnupiravir (0/47) as compared to placebo (6/25). No safety signals were …

… Molnupiravir, a specific SARS-CoV-2 … of molnupiravir, typically used to treat patients suffering
from COVID-19. Chlorophyllins, antioxidants derived from natural plant chlorophyll, are safe…

… -derived lineages, will be an important consideration for assessing the effects and
evolutionary safety of this drug. Our results are consistent with recent observations in …

… SARS-CoV-2 continues to unfold all over the world. The development of novel effective antiviral
drugs to fight against SARS-CoV… Recently, molnupiravir is a prodrug antiviral medication …